LAS VEGAS, NV - 
(NewMediaWire) - March 13, 2024 - BHPA Inc (OTC: BHPA) today announced a merger with Aquiva Medical Inc., a cutting-edge biotech company which develops, produces and manufactures specialized wound dressings and transdermal patches.
Aquiva Medical Inc. is a Nevada Company leveraging its proprietary technology HiPNA (Hydrogel with Inter-Penetrating Network Anchor) toward the development of innovative products to satisfy the unmet needs in wound care, skin care, as well as healthcare markets. Aquiva has developed a novel hydrogel material, AQUIPHER™, with many unique properties that surpasses industry standards, making AQUIPHER™ an ideal material for various applications, including moist wound dressings, and active ingredient releasing patches for skin care, wound care, sleep aid and health supplements, and transdermal drugs. Aquiva has a well-established partnership network with strong capabilities in contract development of potential products for clients and is aiming to expand our service to the fields that traditional transdermal delivery system couldn’t reach.
Kevin Tseng, CEO of Aquiva, said, “We are pleased to have successfully completed the merger with BHPA. Moving forward, we will actively leverage the strengths of our AQUIPHER™ hydrogel material to approach potential clients who are seeking ODM/OEM collaboration in developing and manufacturing of transdermal products. Our ultimate goal is to make Aquiva a well-known transdermal patch CDMO (contract development and manufacturing organization).”
About BHPA Inc.
BHPA post-merger is now the business of Aquiva described supra.
The mission of Aquiva is to leverage its proprietary AQUIPHER™ technologies to facilitate the development and manufacturing of transdermal patches with larger varieties of active ingredients and to work with partners to bring these patches to the market.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest reports filed with OTC Markets. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about BHPA Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For more information on Aquiva Medical Inc., please contact us at info@aquivamedical.com or see our website at www.aquivamedical.com.
